Clinical Trial: A Study of MK0431 in Patients WIth Hepatic Insufficiency (0431-017)(COMPLETED)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: An Open-Label, Single Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK0431

Brief Summary: A study to compare the plasma concentrations of MK0431 at different times in patients with hepatic insufficiency vs healthy control subjects.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: the plasma and urine pharmacokinetic parameters of MK0431 [ Time Frame: measured at predose, 0.5, 1,1.5, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 24, 32, 48, 72 and 96 hours post dose ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Side effects, physical exam, lab safety data, urging drug screen, ECG and vital signs [ Time Frame: throughout study and at 12 weeks ]

Original Secondary Outcome: Same as current

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: June 11, 2008
Date Started: April 2004
Date Completion:
Last Updated: August 18, 2015
Last Verified: August 2015